Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -50.80% is 33% above its 4-year average of -75.49%, near the high end of its 4-year range (-469.38%–-22.85%).
As of the fiscal period ended Tuesday, June 30, 2026. 65.24% above its 12-month average of -146.16%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -50.80%.
RETURN ON EQUITY (ROE)
-50.80%
RETURN ON EQUITY (ROE) AVG TTM
-146.16%
RETURN ON EQUITY (ROE) AVG 3Y
-119.64%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+65.24%
CURRENT VS 3Y AVG
+57.54%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-36.00%
median of 388 covered companies
CURRENT VS SECTOR MEDIAN
-41.08%
vs the sector median at left
Cognition Therapeutics, Inc.
Market Cap
$83.96M
Return on Equity (ROE)
-50.80%
TTM Avg
-146.16%
3Y Avg
-119.64%
5Y Avg
N/A
Market Cap
$84.00M
Return on Equity (ROE)
-309.44%
TTM Avg
-515.53%
3Y Avg
-464.77%
5Y Avg
-329.14%
Market Cap
$83.49M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$84.70M
Return on Equity (ROE)
N/A
TTM Avg
1.45%
3Y Avg
25.22%
5Y Avg
-14.52%
Market Cap
$84.75M
Return on Equity (ROE)
-85.65%
TTM Avg
-57.41%
3Y Avg
-45.73%
5Y Avg
-8.61%
Market Cap
$86.69M
Return on Equity (ROE)
45.93%
TTM Avg
16.96%
3Y Avg
-19.36%
5Y Avg
-13.87%
Market Cap
$81.22M
Return on Equity (ROE)
-114.06%
TTM Avg
-50.52%
3Y Avg
-45.18%
5Y Avg
-45.18%
Market Cap
$87.86M
Return on Equity (ROE)
-150.95%
TTM Avg
-77.89%
3Y Avg
-62.90%
5Y Avg
-47.80%
Market Cap
$88.21M
Return on Equity (ROE)
2.51%
TTM Avg
-5.84%
3Y Avg
-10.75%
5Y Avg
-7.81%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cognition Therapeutics, Inc. (CGTX) | $83.96M | -50.80% | -146.16% | -119.64% | N/A |
| Humacyte, Inc. (HUMA)vs › | $84.00M | -309.44% | -515.53% | -464.77% | -329.14% |
| Conexeu Sciences Inc. (CNXU)vs › | $83.49M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.70M | N/A | 1.45% | 25.22% | -14.52% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | -85.65% | -57.41% | -45.73% | -8.61% |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 45.93% | 16.96% | -19.36% | -13.87% |
| Citius Oncology, Inc. (CTOR)vs › | $81.22M | -114.06% | -50.52% | -45.18% | -45.18% |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | -150.95% | -77.89% | -62.90% | -47.80% |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 2.51% | -5.84% | -10.75% | -7.81% |
| electroCore, Inc. (ECOR)vs › | $91.33M | N/A | 329.82% | 69.21% | 21.28% |
ROE
-50.8%
ROA
-43.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -50.80% |
| 2026-03-31 | -65.45% |
| 2025-12-31 | -68.53% |
| 2025-09-30 | -76.61% |
| 2025-06-30 | -469.38% |
| 2025-03-31 | -271.39% |
| 2024-12-31 | -181.18% |
| 2024-09-30 | -236.64% |
| 2024-06-30 | -135.09% |
| 2024-03-31 | -99.68% |
| 2023-12-31 | -105.37% |
| 2023-09-30 | -78.92% |
| 2023-06-30 | -66.03% |
| 2023-03-31 | -66.32% |
| 2022-12-31 | -53.16% |
| 2022-09-30 | -59.90% |
| 2022-06-30 | -45.65% |
| 2022-03-31 | -32.37% |
| 2021-12-31 | -22.85% |
